<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797493</url>
  </required_header>
  <id_info>
    <org_study_id>5061</org_study_id>
    <nct_id>NCT05797493</nct_id>
  </id_info>
  <brief_title>Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer</brief_title>
  <acronym>PICASSO</acronym>
  <official_title>Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The scope of the PICASSO project is to apply an innovative patient-based pan-omic approach to&#xD;
      immune-assays, that will include multi-omics tumour characterization (genome, proteome,&#xD;
      transcriptome), blood immune-cells and cytokine profiling, serological screening for&#xD;
      paraneoplastic autoantibodies, clinical and metabolic measurements.&#xD;
&#xD;
      The PICASSO project is aimed to validate in real world population the predictive role of SCLC&#xD;
      transcriptomic classification (particularly, I-SCLC subtype) and to explore correlations with&#xD;
      dynamic changes in peripheral blood immunity. Additionally, investigators expected to&#xD;
      validate the predictive/prognostic role of emerging new variables, including&#xD;
      metabolic-induced meta-inflammation alterations and subclinical auto-immunity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2022</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Anticipated">June 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Time from treatment start until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Time from treatment start to the date of death from any cause, assessed up to 60 months</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>ES-SCLC</arm_group_label>
    <description>ES-SCLC receiving upfront chemo-immunotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Upfront chemo-immunotherapy</description>
    <arm_group_label>ES-SCLC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ES SCLC patients treated with first line chemo-immunotherapy (EP-IO&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. histologically- or cytologically-documented extensive-stage SCLC&#xD;
&#xD;
          2. to have received upfront treatment with Cisplatin/Carboplatin, etoposide and anti&#xD;
             PD1/PD-L1 inhibitors&#xD;
&#xD;
          3. No evidence of brain metastases at diagnosis&#xD;
&#xD;
          4. ECOG PS 0-2&#xD;
&#xD;
          5. adult patients (aged â‰¥ 18 years) at diagnosis;&#xD;
&#xD;
          6. signing of informed consent approved by the local Ethic Committee&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emilio Bria, Prof.</last_name>
    <phone>+39 0630156318</phone>
    <email>emilio.bria@policlinicogemelli.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione Policlinico Gemelli IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilio Bria, Professor</last_name>
      <phone>0630155202</phone>
      <phone_ext>+39</phone_ext>
      <email>emilio.bria@policlinicogemelli.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 16, 2023</study_first_submitted>
  <study_first_submitted_qc>April 2, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>April 2, 2023</last_update_submitted>
  <last_update_submitted_qc>April 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</investigator_affiliation>
    <investigator_full_name>Bria Emilio</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>sclc</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

